Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Primary outcome measure:
- Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and
Dexamethasone.
Secondary outcome measures:
- Organ response rate.
- Predictors of response (cardiac biomarkers, serum free light chains).
- Toxicity
- Safety (type, frequency, severity and relationship of adverse events to the study drug).
- Duration of response.
- Time to progression.
- Overall survival